SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Microcap & Penny Stocks : ABMI... Anyone else out there have this stock? LET'S TALK

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: PETE DARRUDA who wrote ()12/6/1996 9:05:00 PM
From: Bill Fortune III   of 37
 
To Pete Darruda:

Just a little info that I received from Kostech SmallCap Research.

Another attractive feature of this emerging company is the consolidation ocurring in this field. According to a medical device review "Charting New Territories in Minimally Invasive Surgery", written by Oppenheimer & Co.'s analysts John Calcagnini and Justin Vaicek (9/20/96) "the worldwide stent market will continue to consolidate as the leading cardiovascular device companies tap smaller manufacturers to secure technology and patent rights." The analysts also stated, "We suspect that smaller manufacturers will be willing to sell, given the tidy sums being offered

This puts ABMI in a unique position, being a small company in a very large industry which is prone to consolidation. ABMI holds patents on intellectual properties very similar to, if not more advanced, than those currently being acquired for hundreds of millions of dollars. The Company's President and CEO, Mr. Steven B. Rash stated, "If our patented stent technology possesses only half the value Medtronic, Inc. paid for Instent's non-patented stents, that would account for over $100-million in valuation on this core
technology alone." Instent, Inc., a tiny stent manufacturer with no FDA approvals and only $2.4-million in revenues last year, was acquired by Medtronic, Inc. for over $214-million earlier this year.

If ABMI were to be acquired, based solely on multiples recently paid for companies and/or similar technologies, it would appear conservative to give the Company a valuation of not less than $200-million which would provide for a speculative share price of around $7.50. The stock is now trading at just over $1. We anticipate further developments soon and will do updates as events occur.

CONTACT: Thomas E. Waite & Associates Inc. 407-324-1606

or visit the company's new website at americanbiomed.com

Kostech SmallCap Research can be reached at:
kostech.com

COPYRIGHT (c) 1996 by Kostech SmallCap Research. ALL RIGHTS RESERVED. While it is our intent to research and locate companies which will provide profitable investments, we are not liable for any investment decisions by our subscribers. Past performance of previously featured companies does not guarantee the future success of a currently featured company. Contact the company featured as well as a licensed financial advisor before making any investment decision.

Bill Fortune III
Minnesota
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext